Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat
Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat
Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat
Submitted by
admin
on October 18, 2021 - 10:55pm
Source:
BioPharma Dive
News Tags:
Boehringer Ingelheim
AbbVie
Humira
interchangeable biosimilars
biosimilars
Cyltezo
FDA
Headline:
Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat
snippet:
When lower-cost versions of AbbVie's top-selling drug Humira launch in the U.S. in 2023, pharmacists will be able to swap at least one of them for the branded product without a specific prescription to do so.
Do Not Allow Advertisers to Use My Personal information
